Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Common Equity (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Common Equity for 16 consecutive years, with $8.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 27.35% year-over-year to $8.3 million, compared with a TTM value of $8.3 million through Sep 2025, up 27.35%, and an annual FY2024 reading of $7.7 million, up 3.93% over the prior year.
  • Common Equity was $8.3 million for Q3 2025 at China Pharma Holdings, up from $6.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $8.3 million in Q3 2025 and bottomed at $2.8 million in Q3 2022.
  • Average Common Equity over 5 years is $6.2 million, with a median of $6.5 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 58.64% in 2022, then soared 115.56% in 2023.
  • Year by year, Common Equity stood at $6.0 million in 2021, then dropped by 28.71% to $4.3 million in 2022, then surged by 73.77% to $7.5 million in 2023, then grew by 3.93% to $7.7 million in 2024, then increased by 7.31% to $8.3 million in 2025.
  • Business Quant data shows Common Equity for CPHI at $8.3 million in Q3 2025, $6.5 million in Q2 2025, and $7.0 million in Q1 2025.